IL2 and cancer: Still, exogenous IL-2 stimulates other regulatory immune cells such as Treg cells that inhibit the activity of transferred NK cells 14 and elevated serum concentration of soluble IL-2 receptor in cancer patients 11 may act as an antagonist against injected IL-2, reducing the percentage of activated NK cells.